Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clozapine
Drug ID BADD_D00511
Description A tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.
Indications and Usage For use in patients with treatment-resistant schizophrenia.
Marketing Status Prescription; Discontinued
ATC Code N05AH02
DrugBank ID DB00363
KEGG ID D00283
MeSH ID D003024
PubChem ID 135398737
TTD Drug ID D0Z1RV
NDC Product Code 57664-345; 0904-7088; 16729-141; 71554-025; 0093-3086; 51079-921; 55154-3568; 60687-404; 0378-3815; 51407-086; 0093-3087; 52817-601; 76072-1010; 0378-0972; 60687-548; 51862-274; 60429-989; 64374-004; 70518-3391; 12828-0072; 0378-0825; 60687-415; 53296-0033; 65862-846; 57664-241; 55154-8285; 57664-347; 65015-706; 60429-990; 51862-901; 0378-3813; 51407-085; 63552-062; 63629-2360; 69809-0126; 60687-426; 63629-2361; 72721-1725; 72721-1760; 0093-4404; 0904-7089; 67835-0028; 65862-847; 16729-142; 0378-0860; 57664-211; 51862-903; 0093-7772; 51862-273; 65862-844; 51079-749; 51079-922; 0093-5377; 0904-7087; 63629-2362; 65862-845; 70518-3357; 63552-063; 0093-5416; 69809-0130; 72721-1750; 51079-288; 72721-1770; 0093-4359; 0093-5419; 69809-0127; 0093-5376; 69809-0135; 63629-2359; 0378-0973; 73377-150; 51862-902; 0093-5417; 0093-4405; 51862-900
Synonyms Clozapine | Clozaril | Leponex
Chemical Information
Molecular Formula C18H19ClN4
CAS Registry Number 5786-21-0
SMILES CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Tardive dyskinesiaD(2) dopamine receptorP14416T6716210821369; 10379516; 10893495; 9777180; 10889553
Tardive dyskinesiaD(3) dopamine receptorP35462T0255110821369; 10379516; 10893495; 9777180; 10889553
Tardive dyskinesiaD(4) dopamine receptorP21917T2498310821369; 10379516; 10893495; 9777180; 10889553
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal adhesions12.02.03.006; 07.07.03.0010.008407%Not Available
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abdominal tenderness07.01.05.0040.011210%Not Available
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Abnormal faeces07.01.03.001--Not Available
Abortion spontaneous18.01.04.001--Not Available
Abscess11.01.08.0010.047641%Not Available
Acidosis14.01.03.002--
Acne23.02.01.001--Not Available
Activated partial thromboplastin time prolonged13.01.02.001--
Acute hepatic failure09.01.03.001--Not Available
Acute lymphocytic leukaemia16.01.01.001; 01.10.01.001--Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.001--Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.001--Not Available
Acute psychosis19.03.01.0010.098084%Not Available
Acute respiratory distress syndrome22.01.03.001--
Acute respiratory failure22.02.06.001; 14.01.04.0040.021201%Not Available
Acute stress disorder19.06.06.0010.005605%Not Available
Adenocarcinoma16.16.01.0040.002924%Not Available
Adrenal insufficiency14.11.01.004; 05.01.02.001--
Affective disorder19.04.04.0010.039234%Not Available
Aggression19.05.01.0010.375522%Not Available
Agitation19.06.02.001; 17.02.05.0120.330683%
Agranulocytosis01.02.03.0011.350758%Not Available
Akathisia19.06.02.006; 17.01.02.002--
Akinesia17.01.02.003--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 48 Pages